Peripheral blood progenitor cells

Enabling outpatient transplantation

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Peripheral blood progenitor cells (PBPCs) are becoming the stem cell source of choice for rescuing patients from marrow aplasia after high-dose chemotherapy. Their advantages over bone marrow include avoidance of general anesthesia and more rapid hematologic recovery after transplantation. More rapid engraftment can reduce the risks associated with transplantation and shorten the hospital stay or, under certain circumstances, eliminate it. The cost reductions associated with a shorter stay have made PBPC transplantation cost-competitive with more conventional therapy. The move to outpatient transplantation requires increased patient and family involvement with posttransplantation care, as well as increased patient education and a multidisciplinary care team for the safe transition of patients between care sites. Improvements in outpatient transplantation may incorporate a cooperative care model with the intent of reducing readmission rates and extending this modality to most patients who undergo autologous transplantation.

Original languageEnglish (US)
JournalPharmacotherapy
Volume18
Issue number1
StatePublished - Feb 12 1998

Fingerprint

Blood Cells
Outpatients
Stem Cells
Transplantation
Bone Marrow
Costs and Cost Analysis
Autologous Transplantation
Cell Transplantation
Patient Education
General Anesthesia
Length of Stay
Patient Care
Drug Therapy
Therapeutics

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Peripheral blood progenitor cells : Enabling outpatient transplantation. / McGuire, Timothy R; Tarantolo, S.; Reed, Elizabeth Cecile.

In: Pharmacotherapy, Vol. 18, No. 1, 12.02.1998.

Research output: Contribution to journalArticle

@article{86aadd356a3d4113abef435a305556e8,
title = "Peripheral blood progenitor cells: Enabling outpatient transplantation",
abstract = "Peripheral blood progenitor cells (PBPCs) are becoming the stem cell source of choice for rescuing patients from marrow aplasia after high-dose chemotherapy. Their advantages over bone marrow include avoidance of general anesthesia and more rapid hematologic recovery after transplantation. More rapid engraftment can reduce the risks associated with transplantation and shorten the hospital stay or, under certain circumstances, eliminate it. The cost reductions associated with a shorter stay have made PBPC transplantation cost-competitive with more conventional therapy. The move to outpatient transplantation requires increased patient and family involvement with posttransplantation care, as well as increased patient education and a multidisciplinary care team for the safe transition of patients between care sites. Improvements in outpatient transplantation may incorporate a cooperative care model with the intent of reducing readmission rates and extending this modality to most patients who undergo autologous transplantation.",
author = "McGuire, {Timothy R} and S. Tarantolo and Reed, {Elizabeth Cecile}",
year = "1998",
month = "2",
day = "12",
language = "English (US)",
volume = "18",
journal = "Pharmacotherapy",
issn = "0277-0008",
publisher = "Pharmacotherapy Publications Inc.",
number = "1",

}

TY - JOUR

T1 - Peripheral blood progenitor cells

T2 - Enabling outpatient transplantation

AU - McGuire, Timothy R

AU - Tarantolo, S.

AU - Reed, Elizabeth Cecile

PY - 1998/2/12

Y1 - 1998/2/12

N2 - Peripheral blood progenitor cells (PBPCs) are becoming the stem cell source of choice for rescuing patients from marrow aplasia after high-dose chemotherapy. Their advantages over bone marrow include avoidance of general anesthesia and more rapid hematologic recovery after transplantation. More rapid engraftment can reduce the risks associated with transplantation and shorten the hospital stay or, under certain circumstances, eliminate it. The cost reductions associated with a shorter stay have made PBPC transplantation cost-competitive with more conventional therapy. The move to outpatient transplantation requires increased patient and family involvement with posttransplantation care, as well as increased patient education and a multidisciplinary care team for the safe transition of patients between care sites. Improvements in outpatient transplantation may incorporate a cooperative care model with the intent of reducing readmission rates and extending this modality to most patients who undergo autologous transplantation.

AB - Peripheral blood progenitor cells (PBPCs) are becoming the stem cell source of choice for rescuing patients from marrow aplasia after high-dose chemotherapy. Their advantages over bone marrow include avoidance of general anesthesia and more rapid hematologic recovery after transplantation. More rapid engraftment can reduce the risks associated with transplantation and shorten the hospital stay or, under certain circumstances, eliminate it. The cost reductions associated with a shorter stay have made PBPC transplantation cost-competitive with more conventional therapy. The move to outpatient transplantation requires increased patient and family involvement with posttransplantation care, as well as increased patient education and a multidisciplinary care team for the safe transition of patients between care sites. Improvements in outpatient transplantation may incorporate a cooperative care model with the intent of reducing readmission rates and extending this modality to most patients who undergo autologous transplantation.

UR - http://www.scopus.com/inward/record.url?scp=0031974913&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031974913&partnerID=8YFLogxK

M3 - Article

VL - 18

JO - Pharmacotherapy

JF - Pharmacotherapy

SN - 0277-0008

IS - 1

ER -